Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | BRD2 | P25440 | 2/20 | 0.56 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.56 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12098544 | 0.86 | BRD4 (0.52) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL12098660 | 0.84 | BRD4 (0.73) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18308355 | 0.79 | BRD4 (0.57) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL12098940 | 0.79 | BRD4 (0.61) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL12099301 | 0.78 | BRD4 (0.77) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18308314 | 0.77 | BRD4 (0.57) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18904315 | 0.76 | BRD4 (0.70) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18308406 | 0.76 | BRD4 (0.58) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18308343 | 0.76 | BRD4 (0.55) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL12098915 | 0.76 | BRD4 (0.74) | BRD4CYP3A4CYP2C9BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2496576-B1 | IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8557984-B2 | Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557984-B2 | Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557984-B2 | Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120232074-A1 | Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-09-13 | — | — | US | disclosed |
| US-20120232074-A1 | Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-09-13 | — | — | US | disclosed |
| US-20120232074-A1 | Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-09-13 | — | — | US | disclosed |
| WO-2011054846-A1 | IMIDAZO [4, 5-C] QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232074-A1 | Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors | BRD4, BRD3, BRPF3 | BRD4 1/4885CYP3A4 1579/4885CYP2C9 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.